Health-care companies fell slightly as traders anticipated deal activity in the sector.
Swiss conglomerate Nestlé plans to explore strategic options for the Palforzia peanut-allergy drug, effectively putting it up for sale just two years after acquiring its developer in a $2.6 billion deal.
Drugmaker Horizon Therapeutics is sounding out potential buyers as Big Pharma companies continue to seek acquisitions that would bolster their product lines, despite miscues like Nestlé's.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
11-29-22 1722ET
